CD274 and non-small cell lung carcinoma: reviewed registrative trials concerning advanced non-squamous non-oncogene-addicted NSCLC and concluded that those with PD-L1 expression <50% benefit from first-line combinations of Pembrolizumab or Atezolizumab with chemotherapy, or second-line therapy with antiangiogenic agents plus Docetaxel (Table 2).